Rehmann Capital Advisory Group’s Sage Therapeutics SAGE Stock Holding History

Rehmann Capital Advisory Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$6.73K	Buy	48 +4	+9%	+$669	﹤0.01%	1141
2019 Q2	$8.05K	Buy	44 +17	+63%	+$2.9K	﹤0.01%	1414
2019 Q1	$4.29K	Hold	27	–	–	﹤0.01%	1568
2018 Q4	$2.59K	Sell	27 -72	-73%	-$8.24K	﹤0.01%	1398
2018 Q3	$14K	Buy	99 +7	+8%	+$1.08K	﹤0.01%	1245
2018 Q2	$14.4K	Buy	92 +20	+28%	+$3.14K	﹤0.01%	1215
2018 Q1	$12K	Buy	+72	New	+$12.2K	﹤0.01%	1248

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Rehmann Capital Advisory Group's SAGE Position: Q3 2019 in Review

Rehmann Capital Advisory Group increased its Sage Therapeutics (SAGE) stake by 9.1% in Q3 2019, buying an estimated $669 and bringing the position to 48 shares worth $6.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

Rehmann Capital Advisory Group first reported a position in SAGE in Q1 2018 and has held it in 7 quarters since. The position peaked at $14.4K in Q2 2018. 285 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

Rehmann Capital Advisory Group held 48 shares of Sage Therapeutics worth $6.73K as of Q3 2019.
Rehmann Capital Advisory Group bought 4 Sage Therapeutics shares in Q3 2019, an estimated $669.
Sage Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1141 holding.
Rehmann Capital Advisory Group first reported a position in Sage Therapeutics in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Sage Therapeutics position peaked at $14.4K in Q2 2018.
285 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.